Research for hepatocarcinogenesis and new therapeutic targets in hepatocellular carcinoma with or without HBV/HCV suppression

2018 Fiscal Year Final Research Report

• Project/Area Number: 17K15932
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Gastroenterology
• Research Institution: Tokyo Medical and Dental University
• Principal Investigator: KAWAI-KITAHATA Fukiko (河合) 東京医科歯科大学, 医学部附属病院, 特任助教 (00755580)
• Research Collaborator: TANAKA Shinji ; TANABE Minoru ; ASAHINA Yasuhiro ; KAKINUMA Sei ; KANEKO Shun ; KAMIYA Akihide
• Project Period (FY): 2017-04-01 – 2019-03-31
• Keywords: 肝細胞癌 / 遺伝子変異

Outline of Final Research Achievements

We investigated cancer-related genes and viral integration using next generation sequencing in HCC tissues.
In HBs antigen positive HCC, HBV suppression by NUCs may reduce TERT promoter mutation, but not HBV integration. In contrast, HCV eradication has a small influence on gene mutational status in HCV-related HCC. About 10% of NBNC HCC with prior HBV infection had HBV integration and these were developed from normal liver at a younger age. These results above are important and contribute to clarify the mechanisms of the genomic features including HBV integration and the underlying pathway responsible for hepatocarcinogenesis among different etiology and status of viral suppression.

Free Research Field

肝臓

Academic Significance and Societal Importance of the Research Achievements

近年課題となっているHCV排除後やHBV制御下において肝癌を発症した症例に関して癌関連遺伝子変異やウイルスDNAのヒトゲノムへの挿入を調べた。病因やウイルス制御状態により発癌過程が異なる可能性を示しその発癌機構の一端を解明したことにより、発癌予測や治療方針など臨床的な知見となり得る。